Literature DB >> 34279572

Will CMS Find Aducanumab Reasonable and Necessary for Alzheimer Disease After FDA Approval?

Kevin A Schulman1,2, Michael D Greicius3, Barak Richman4.   

Abstract

Entities:  

Year:  2021        PMID： 34279572     DOI： 10.1001/jama.2021.11768

Source DB:  PubMed          Journal:  JAMA        ISSN： 0098-7484            Impact factor:   56.272


× No keyword cloud information.
  7 in total

Review 1.  Recent update on the heterogeneity of the Alzheimer's disease spectrum.

Authors:  Kurt A Jellinger
Journal:  J Neural Transm (Vienna)       Date:  2021-12-17       Impact factor: 3.575

2.  Instead of wasting money on aducanumab, pay for programs proven to help people living with dementia.

Authors:  Lauren J Hunt; Krista L Harrison; Kenneth E Covinsky
Journal:  J Am Geriatr Soc       Date:  2021-09-16       Impact factor: 5.562

3.  Cost-effectiveness of Aducanumab and Donanemab for Early Alzheimer Disease in the US.

Authors:  Eric L Ross; Marc S Weinberg; Steven E Arnold
Journal:  JAMA Neurol       Date:  2022-05-01       Impact factor: 29.907

Review 4.  The value of anticancer drugs - a regulatory view.

Authors:  Francesco Pignatti; Ulla Wilking; Douwe Postmus; Nils Wilking; Julio Delgado; Jonas Bergh
Journal:  Nat Rev Clin Oncol       Date:  2021-12-06       Impact factor: 66.675

Review 5.  [Disease-modifying treatment approaches for Alzheimer's disease].

Authors:  Lutz Frölich; Lucrezia Hausner
Journal:  Nervenarzt       Date:  2021-11-04       Impact factor: 1.297

6.  Exosomes derived from bone-marrow mesenchymal stem cells alleviate cognitive decline in AD-like mice by improving BDNF-related neuropathology.

Authors:  Sen Liu; Min Fan; Jing-Xian Xu; Long-Jun Yang; Cong-Cong Qi; Qing-Rong Xia; Jin-Fang Ge
Journal:  J Neuroinflammation       Date:  2022-02-07       Impact factor: 8.322

Review 7.  Neuroinflammation represents a common theme amongst genetic and environmental risk factors for Alzheimer and Parkinson diseases.

Authors:  Rachel J Boyd; Dimitri Avramopoulos; Lauren L Jantzie; Andrew S McCallion
Journal:  J Neuroinflammation       Date:  2022-09-08       Impact factor: 9.587
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.